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1. Introduction
The incidence of diabetes and associated metabolic disorders has tripled over recent decades
and continues to rise at an alarming rate. Currently, 382 million individuals worldwide are
estimated to have diabetes and this number is believed to increase to 592 million by 2035 [1];
the vast majority of the cases is type 2 diabetes mellitus (T2DM).
Taking into account the number of patients impacted by T2DM and its long-term consequences
in terms of morbidity, mortality and economic costs, there is considerable interest in under‐
standing the contribution of non-traditional risk factors to the diabetes epidemic, especially
concerning environmental chemicals and particularly endocrine-disrupting chemicals (EDCs).
Researches addressing the role of environmental chemicals in the development of metabolic
disorders, like obesity and T2DM, have rapidly expanded. Epidemiological and experimental
evidence suggest an association between exposure to EDCs and T2DM, especially since the
exposure to chemicals increased massively in the last decade.
In this chapter we tried to elucidate the following issues: (1) the concept of EDCs; (2) human
exposure to EDCs; (3) particular concepts related to EDCs; (4) mechanisms of EDCs action
involved in the development of T2DM; (5) evidence of T2DM in animal models; (6) epidemio‐
logical data linking EDCs exposure to T2DM and (7) challenges in EDCs research.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and eproduction in any medium, provided the original work is properly cited.
2. The concept of EDCs
Originally articulated in the early 1990s by Colbron [2], the theory of endocrine disruption referes
to exogenous chemicals present in the environment and/or diet that interfere and disrupt
physiological hormonal systems, inducing adverse effects on human and wildlife health. The
term ”endocrine disruptor“ was first used at the Wingspread Conference in Wisconsin, USA
in 1991 for those EDCs, which may lead to an adverse health effect [3]. Initially the term focused
on chemicals with estrogenic activity that would alter reproductive function, commonly
referred to as environmental estrogens or xenoestrogens; it has expanded to compounds with
androgenic activity, as well as thyroid-active chemicals [4]. Consequently, different variable
terms appeared, e.g. endocrine disrupter or endocrine disruptor, hormone mimics, hormone
inhibitors or endocrine modulators [5]. Today, these compounds are commonly referred to as
EDCs.
Various attempts to set up a scientific definition of an EDC have been made. Today is generally
wide acceptance of using the WHO definition [6], which is similar with the EU definition [7]:
„An endcorine disruptor is an exogenous substance or mixture that alters function(s) of the endocrine
system and consequently causes adverse health effects in an intact organism, or its progeny, or
(sub)populations”.
EDCs interfere and disrupt physiological hormonal balance inducing adverse effects on
human health through different mechanisms including direct interaction with hormone
receptors, competition on binding and transport proteins or interference with hormone
metabolism (blocking or inducing the synthesis of the hormones). Starting from this definition
there are clearly two requirements for a substance to be defined as an EDCs, namely the
demonstration of an adverse effect and an endocrine disruption mode-of-action. Additionally,
the definition implies proof of causality between the observed adverse effect and the endocrine
disruption mode-of-action.
It is important to underline that the definition of EDC includes the term “adverse” which was
considered as a key criterion to differentiate a genuine EDC from a mere endocrine modulator
(that elicits an adaptative reversible response in endocrine homeostasis). According to WHO
the term “adversity” means: “a change in morphology, physiology, growth, reproduction, develop‐
ment or lifespan of an organism which results in impairment of functional capacity or impairment of
capacity to compensate for additional stress or increased susceptibility to the harmful effects of other
environmental influences.” [8].
This definition is not covering the potential or indicates EDC. A potential (or suspected) EDC
may alter function(s) of the endocrine system and consequently may cause adverse health
effects, while a substance with indication of endocrine disrupting properties (called indicated
EDC) might be expected to lead to endocrine disruption in an intact organism, or its progeny,
or (sub)populations.
The need for an expansion of the general term to potential EDCs is reflected on the new
Guidance document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine
Disruption (OECD 2011) [9]: “A possible endocrine disrupter is a chemical that is able to alter the
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functioning of the endocrine system but for which information about possible adverse consequences of
that alteration in an intact organism is uncertain”.
Recently, the Endocrine Society published a statement of principles on endocrine disruptors
[10] in which another definition of an EDC has been proposed: “An EDC is an exogenous chemical,
or mixture of chemicals, that interferes with any aspect of hormone action.” This definition empha‐
sizes that the ability of a chemical to interfere with hormone action is of itself a reliable predictor
for adverse outcomes.
A wide variety of chemicals act as EDCs. The Endocrine Disruption Exchange List (TEDX) to
date lists almost 1000 endocrine disruptors [11]. The group of EDCs is highly heterogeneous
and includes synthetic chemicals used as industrial solvents/lubricants and their by-products
(persistent organic pollutants – POPs, dioxins like 2,3,7,8-tetrachlorodibenzo-p-dioxin –
TCDD), plastics (bisphenol A – BPA), pesticides (as dichlorodiphenyltrichloroethane – DDT),
plasticizers (phthalates like diethylhexyl phthalate – DEHP), heavy metals (arsenic, cadmium),
tributyl tin (TBT), fungicides (vinclozolin) and pharmaceutical agents (diethylstilbestrol –
DES). POPs comprise a broad class of organohalides, including polychlorinated biphenyls
(PCBs), polybrominated biphenyls (PBBs) and organochlorine pesticides.
However, one should keep in mind that there is also a large number of EDCs of natural origin
occurring in plants consumed as food and also some secondary metabolites from fungi that
may contaminate food. Examples of EDCs with oestrogenic activity are present in soy (e.g.
genistein and daidzein), mycotoxins in cereals (e.g. zearalenone), goitrogens in cabbage (with
the potential to inhibit iodine uptake) and glycirrhizine in liquorice (with the potential to
disturb the mineralocorticoid system) [12].
EDCs are widely dispersed in the environment. Some are persistent, having long half-lives
[13], while others are rapidly degraded in the environment or human body or may be present
for only short periods of time but at critical periods of development, considered windows of
susceptibility.
The effects of EDCs are observed especially on sensitive groups (foetus and child), based
on their  susceptibility  to  hormonal  effects  [14].  Therefore,  for  these  groups  the  adverse
effects  may occur  at  concentrations  that  are  far  below levels  that  would  be  considered
harmful in the adult [15]
Of a special concern are EDCs such as phthalates [16], PBBs [17] and BPA, detected in pregnant
women, fetuses and newborns, taking into account that exposure occuring early in pregnancy
can have short-term health effects, while exposure later or during early childhood may induce
cognitive and developmental deficiencies [18].
Published studies illustrate that in utero developmental period is a critically sensitive window
of vulnerability. Disruptions during this time-frame can lead to subtle functional changes that
may not emerge until later in life [19] or even later to the next generation.
Actually, is considered that in utero and early postnatal exposures play an important role in
the development of reproductive defects, obesity and metabolic syndrome as a result of
inheritable chemical-induced epigenetic changes [20, 21, 22]. As an example of epigenetic
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change involved in reproductive defects one can note the developmental exposure to vinclo‐
zolin causing an increase in spermatogenic cell apoptosis in the adult rats [23]. This sperma‐
togenic defect was found to be transgenerational at least to F4 generation due to a permanent
altered DNA methylation of the male germ-line [21].
Criteria Available data – according to OECD Conceptual Framework [29,30]
Category 1: EDCs
• in vivo data (mode of action
clearly linked to adverse
effects)
• In vivo assays providing data on effects clearly linked to endocrine mechanisms
(OECD, conceptual Framework (CF) level 5)
• On a case-by-case basis, in vivo assays providing data about single or multiple
endocrine mechanisms and effects (OECD, CF levels 3 & 4), combined with other
relevant information
• In special cases, categorization or QSAR approaches may provide the necessary data
in combination with in vivo ADME information and in vitro data
• Reliable and good quality evidence from human cases or epidemiological studies
Category 2a: Suspected EDCs
• in vivo data (mode of action
suspected to be linked to
adverse effects)
or
• in vitro mode of action
combined with toxicokinetic
in vivo data
• In vivo assays providing data on effects linked to endocrine or other mechanisms
(OECD, CF level 5), but where ED mode of action is suspected
• In vivo assays providing data about single or multiple endocrine mechanisms and
effects (OECD, CF levels 3 & 4)
• In some cases, read across, chemical categorization and/or QSAR approaches may
provide the necessary data in combination with in vivo ADME information and in vitro
data
• Good quality epidemiological studies showing associations between exposure and
adverse human health effects related to endocrine systems.
Category 2b: Indicated EDCs
• Some in vitro/in silico
evidence
• In vitro assays providing mechanistic data (OECD, CF level 2)
• QSAR, read-across, chemical categorization, ADME information (OECD, CF level 2)
• System biology methods indicating associations between the substance and adverse
human health effects related to endocrine systems.
Table 1. Classification of EDCs based on Danish criteria
Many other chemicals have also been implicated in promoting toxicity for multiple genera‐
tions, including BPA [24] or pesticides [25], but in these cases the multigenerational effects
involved direct exposures, therefore are not considered transgenerational because they are not
transmitted solely through the germ cells. Only effects appearing in the F3 generation are
considered to be truly transgenerational [26].
There are multiple classifications of EDCs, based on their mechanisms of action (on enzymes,
transport proteins or receptors), the pathways modulated (e.g., xenoestrogens/antiestrogens,
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xenoandrogens/antiandrogens), or the biological outcomes (simulation or inhibition) [27].
However, the best classification is the Danish criteria, based on available data (in vitro, in
vivo and epidemiological studies), which is scientifically legitimated by Hass et al. [28]. Using
this approach, EDCs are divided into 3 categories: category 1, for substances known to produce
endocrine disrupting adverse effects in humans or animal species, category 2a for suspected
EDCs, and category 2b for indicated EDC. Details regarding classification criteria are included
in Table 1.
3. Human exposure to EDCs
Environmental human exposure occurs through a variety of routes and varies widely around
the world. Food ingestion represents the major route by which people are exposed to EDCs.
For example, diet is thought to account for up to 90% of a person’s POPs body burden [31].
Taking into account that these pollutants are accumulated particularly in highly rank preda‐
tors, like fish, in Sweden, consumption of fatty fish from the Baltic Sea is the major source of
POPs, but also dairy products and meat contain these pollutants [32]. Also contaminated
ground water is a major exposure source to inorganic arsenic in the general adult population
in several regions, notably Bangladesh and India [33,34].
Regarding BPA exposure, small amounts of BPA can migrate from polymers to food or water,
especially when heated. The human consumption of BPA from epoxy-lined food cans alone is
estimated to be about 6.6 μg per person per day [35]. BPA has been found in concentrations of
1–10 ng/ml in serum of pregnant women, in the amniotic fluid of their fetus, and in cord serum
taken at birth [36]. Moreover, BPA concentrations up to 100 ng/g were reported in placenta
[37], but also in breast adipose tissue, taking into account its lipophilicity.
With the increase in household products containing pollutants and the decrease in the quality
of building ventilation, indoor air has become a significant source of EDCs exposure, via
inhalation [38]. Published studies [39,40] suggest that contaminated house dust may be the
major source of PBBs body burden (up to 82%).
Other routes of exposure include the dermal contact (e.g. parabens or triclosan), via lactation
or infants fed formula (especially for phytoestrogens as genistein or BHA). A published study
[41] reported that urinary concentrations of genistein and daidzein were about 500-fold higher
in infants fed with soy formula compared with those fed cow’s milk formula.
4. Particular concepts related with EDCs
For decades, two major interrelated concepts are particularly addressed regarding EDCs: the
low dose effect and non-monotonous dose–response relationships (e.g. “inverted U-shapes”
of the dose–response curve).
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Like hormones, some of EDCs act at low or very low doses, other variable, therefore their blood
levels are not reflecting the real activity [42].
The traditional toxicological endpoints are not sufficient to preclude the adverse outcome.
Therefore for the endocrine-sensitive endpoints it was suggested to set the NOAEL (no
observed adverse effect level) or the LOAEL (lowest observed adverse effect level) from
traditional toxicological studies or even below the range of human exposures, as the highest
dose in experiments designed to test EDCs. For example, low-dose effects of BPA should be
investigated in rodents exposed to 400 μg/kg bw/day BPA or lower, because this concentration
produces levels of unconjugated BPA in the range of human blood concentrations [43]; this
level is incomparable lower with the classical developmental studies, where LOAEL corre‐
sponds to 50 mg/kg bw/day [44]. Actually, most effects were seen at doses below 50 μg/kg [43],
so even lower concentration than those normally detected in humans may induce adverse
effects.
The effect of EDCs also depends on the type of tissue and the expression of hormone receptors
on those cells, therefore the effect is considered to be tissue specific. Taking into account that
some EDCs can exhibit different potencies on different receptors isoforms (e.g ERα or ERβ),
the effect is also receptor-selective.
A well-known example is related to methyl-and propylparaben. In vitro, both parabens are
binding to estrogen receptors (ERα and β), but methylparaben exhibits a weak estrogenic
activity, while for propylparaben the estrogenic potential is a stronger [45,46]; in vivo parabens
estrogenic potencies are comparable [46]. The relative activity of parabens compared with
estradiol (E2) is 1000 times lower [47]. Interesting, the estrogenic effects of parabens are not
modulated only by estrogen receptors, but are also related to the inhibition of sulfotransferases
in skin, elevating the local level of free estrogens [48].
By comparison with native hormones, EDCs exhibits lower affinity for hormone receptors,
with some exceptions, such as TBT, which is the most potent agonist of retinoid-X-receptor
and PPARγ (peroxisome proliferator activating receptor subtype gamma) in the low nano‐
molar range [49].
The shape of the dose-response curve for EDCs does not follow the usual dose-response curve.
The curve can have a sigmoidal shape (relationship between dose and effect occure based on
the saturability of the receptors), but in general EDCs do act via a non-monotonic dose-
response relationship [43]. In this case, the slope of the curve changes sign somewhere within
the range of the examined doses. In other words, some effects can be seen at very low doses,
while slightly higher doses can show no effects and then, at high doses, some different types
of effects may be found.
For  example,  hypoglycaemic  or  hyperglycaemic  effects  of  TCDD  (tetrachlorodibenzo-p-
dioxin) observed in animal models are dose-dependent. Repeated low-dose of TCDD (500
ng/kg p.o.)  reduced glucokinase gene expression in mice [50],  while higher dosage (12.8
μg/kg TCDD p.o)  induced a  significantly  reduction of  serum glucose  levels  [51].  More‐
over, a higher dose of TCDD (116 μg/kg i.p.) impaired insulin-stimulated glucose uptake
in mice [52].
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Another example is BPA. On isolated pancreatic islets of Langerhans BPA induced an increase
of insulin content following an inverted U-shape dose response curve, with a significant effect
observed at 1 nM and 10 nM BPA compared to vehicle. Higher concentrations of BPA (1 μM)
produced no increase in insulin content [53].
A similar non-monotonic behaviour is exhibited by BPA in animal studies where treatment
with high dosage (BPA 100 μg/kg bw/day) twice per day for 4 days increased pancreatic insulin
content, produced hyperinsulinemia, and induced insulin resistance in adult male mice [54]
while sustained exposure of pregnant mouse dams to lower levels of BPA (10 μg/kg bw/day)
from gestation day 9–16 impaired glucose tolerance, increased plasma insulin, triglycerides
and leptin concentrations, thus revealing the ability of BPA to alter pancreatic function and
metabolic parameters [55].
Also PBBs, especially PBDE-153 (polybrominated diphenyl ether) showed an inverted U-
shaped association with metabolic syndrome in epidemiological study in humans [56].
So, the most important effects of EDCs observed in animal models are those that occur at low
doses, similar with the level of human environmental exposure, therefore only these toxico‐
logical data should be corroborated with epidemiological studies.
We also should note that for the assessment of EDCs effects, the assumption of an experimental
threshold (like a NOAEL) is questionable. A first reason is related to the lack of adversity for
some endpoints investigated (e.g., uterotrophic assay). A second reason is connected with the
difficulties to establish it. According to Blair et al. [57], a threshold could be established in the
absence of endogenous hormone at some life stage, if the endogenous hormone induces no
adverse effect or if there is effective homeostatic control. Even if a threshold does exist, for a
certain endpoint, taking into account the population variability and the connection with
already ongoing biological process (EDCs exhibit additive effects), the threshold will not be
observable.
5. Mechanisms of action involved in development of T2DM
In addition to the classical pathway modulated by EDCs (as interaction with aryl hydrocar‐
bon receptor (AhR) or nuclear hormone receptors, in particular estrogens, androgens and
thyroid receptors), it was observed that EDCs exhibit the capacity to modulate signalling
pathways involved in energy regulation, in general,  and glucose homeostasis in particu‐
lar.  EDCs can decrease insulin sensitivity,  impair β-cell  insulin production, impair cellu‐
lar insulin action or alter the intermediary metabolism. All these mechanisms contribute to
the pathogenesis of T2DM. Experimental data revealed that one EDC acts on different levels
and  receptors,  therefore  the  ultimate  effect  on  insulin  action  may  be  the  result  of  all
pathways involved (Table 2).
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Compound Mechanisms of action Primary effects
BPA (+)ERα via ERK1/2 ↑  β-cell insulin content
↓  GLUT4
(+) ER-GPR30 ↑  β-cell insulin content
↑  CREB phosphorylation ↑  [Ca2+]i
↑  Akt phosphorylation
↑  PI3-kinase activity
↓  IRS activity
Potent antagonist of PPARγ
(-) PDI
↑  TNF-α, IL-6; ↓  adiponectin release
↓  IR phosphorylation
PCBs
(especially PCB-77)
(+) AhR ↑  TNF-α, IL-6; ↑  MCP-1
↓  PEPCK
(+) MAPK1/2
(+) CaMK2
↑  [Ca]i
(-) IRS-1 phosphorylation
(-)Akt phosphorilation Insulin resistance
↑  oxidative stress ↑  β-cell death
Legend: (+) activate; (-) inhibit; ↑ increase; ↓ decrease; ER-estrogenic receptors; ERK1/2 extracellular regulated kin‐
ase1/2; GLUT4 – glucose transporter type4; ER-GPR30-membrane G protein related estrogen-receptor; CREB-cAMP re‐
sponse element-binding protein; [Ca2+]i - intracellular calcium ion levels; IRS – insulin receptor substrate 1; PI3 -
phosphatidylinositol-4,5-bisphosphate 3-kinase; PPARγ - peroxisome proliferator-activated receptor gamma; TNF-α -
tumor necrosis factor-α; IL-6 interleukin-6; PDI - protein disulfide isomerase; IR – insulin receptor; AhR -aryl
hydrocarbon receptor; MCP-1- monocyte chemoattractantprotein-1;PEPCK- phosphoenolpyruvate carboxykinase;
MAPK1/2 - mitogen-activated protein kinase 1/2; CaMK2 - Ca2+/calmodulin-dependent kinase II
Table 2. Example of EDC that acts on multiple pathways
Interestingly, some EDCs such as TCDD [58], PCBs [59], inorganic arsenic [60] or cadmium [61]
that modulate β-cell function, may also play a role in type 1 diabetes mellitus, as a result of
β-cell destruction or dysfunction as well as promotion of β-cell death.
The following mechanisms of action can explain the development of T2DM: (1) activation of
aryl hydrocarbon receptor (AhR) or interaction with estrogenic receptors (ERs); (2) β-cell
dysfunction and impairment of insulin secretion; (3) impairment of cellular insulin action and
(4) alteration of the intermediary metabolism.
5.1. Activation of AhR or interaction with ERs
EDCs can exhibit their metabolic effects through the classical pathways, such as the activation
of AhR or the interaction with ERs. It is well known that AhRs are involved in the glucose
homeostasis [50], therefore activation of AhR or its heterodimerization partner, called ARNT
(AhR nuclear translocator) by EDCs could interfere with glucose uptake. Gunton et al. [62]
revealed that abnormal ARNT expression causes impaired insulin release in human islets, but
it is unclear if this effect is a cause or a consequence of T2DM.
PCBs [63] or PBDE [64] reduce primary hepatocyte glycogen levels and impair gluconeogen‐
esis due to a specific down regulation of phosphoenolpyruvate carboxykinase (PEPCK)
expression, a central regulator of gluconeogenesis. The alteration of PEPCK expression was
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proportional to activation of the AhR, suggesting a direct correlation between AhR activation
and perturbation in intermediary metabolism.
PCBs (especially PCB-77) also impaired glucose homeostasis through another AhR-depend‐
ent  mechanism,  associated  with  an  adipose-specific  increase  in  TNF-α  (tumor  necrosis
factor-α) expression and interleukin-6 (IL-6) levels [65, 66]. In addition to its effects on TNF-
α  and  IL-6,  PCB-77  also  increases  expression  of  MCP-1  (monocyte  chemoattractant
protein-1), an adipocyte-secreted molecule with inflammatory function that contributes to
global insulin sensitivity [67].
The implication of estrogenic receptors (especially ERα) in the pancreatic β-cell insulin content
is confirmed by BPA studies. At physiologically relevant doses, BPA increases pancreatic β-
cell insulin content, the effect being mediated by ERα activation via extracellular regulated
kinase1/2 (ERK1/2) [53]. ERα is also implicated in β-cell survival [68], regulates the glucose
transporter (GLUT4) in skeletal muscle [69] and insulin sensitivity in the liver [70]
Also the non-classical membrane G protein related estrogen-receptor (ER-GPR30), expressed
in pancreatic islets is involved in the effects of estrogens on glucose metabolism, its deficiency
inducing hyperglycemia, impaired glucose tolerance, and elevated blood pressure [71]. GPR30
activation by several EDCs, e.g. BPA could partly contribute to the increase of insulin after
BPA exposure [72]
5.2. Beta-cell dysfunction and impairment of insulin secretion
Taking into account their reduced capacity to fight against chronic oxidative stress and the
lack of detoxification mechanisms, β-cells are the perfect target for EDCs that disrupt their
structure and function or promote death.
Oxidative stress is the mechanism implicated in T2DM induced by exposure to inorganic arsenic.
At relatively low concentrations arsenic-induced oxidative stress produces impairment of
glucose-stimulated insulin secretion [73], while exposure to high concentrations results in
irreversible damage (including oxidative damage) to β-cells followed by apoptosis or ne‐
crosis [74]. Actually, the mechanism behind arsenic-induced oxidative stress is more com‐
plex. Chronic exposure to relative low concentration of arsenite (1–2 μM) produced an adaptive
response, activating the transcription factor NF-E2–related factor 2 (Nrf2). Even if Nrf2 is
generally considered a protective cellular component that induces antioxidant / detoxifica‐
tion enzymes [73], in this case Nrf2 activation that diminishes the reactive oxygen species (ROS)
have a negative impact on insulin secretion. In normal cells, ROS signals produced during
glucose metabolism increase the insulin secretion [75],  thefore arsenic Nrf2-mediated re‐
sponse appears to play an important role in reduced glucose-stimulated insulin secretion.
Inorganic arsenic also promotes β-cell apoptosis via induction of endoplasmic reticulum stress,
but this mechanism is poorly studied and necessitates further investigations [76].
Regarding the interference and impairment of insulin secretion, different examples can be
provided, especially taking into account that insulin secretion is a calcium-dependent process.
On isolated pancreatic β-cells BPA at low concentration (10-9 M) increases the phosphorylation
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of CREB (transcription factor cyclic adenosine monophosphate-response element-binding
protein) via an alternative mechanism, involving a non-classical membrane estrogen receptor
[77], which provokes the closure of K+/ATP channels. As a result the plasma membrane
depolarizes, opening the L-type voltage-dependent calcium channels and increasing intracel‐
lular calcium ion levels [Ca2+]i and triggering insulin secretion [78].
Also abnormal levels of [Ca2+]i and the impairment of insulin secretion were observed on
isolated islet cells exposed to TBT and are associated with the disruption of protein-kinase A
activity [79].
PCB treatment of RINm5F cells resulted in a rapid increase of [Ca2+]i as a result of Ca2+/
calmodulin-dependent kinase II (CaMK2) and mitogen-activated protein kinase 1 and 2
(MAPK 1 and 2) activation [80]. In addition, RINm5F cells exposed to inorganic arsenic (III)
exhibited a reduction of insulin secretion as a result of decreased calcium-dependent calpain-10
activity, a pathway that triggers insulin exocytosis [81]. Arsenic also reduces the β-cell line
proliferation in a dose-dependent manner, as an indirect consequence of the decrease in insulin
secretion.
5.3. Impairment of cellular insulin action
Taking into account that insulin signalling mechanisms are described in detail elsewhere [82],
we present only a short analysis of the insulin signalling cascade in order to provide some
insights into how EDCs might modulate insulin action.
Insulin acts on target cells and stimulates glucose uptake via membrane –bound tertrametric
insulin receptor (IR) with tyrosine kinase activity. Binding to extracellular α-subunits of IR
leads to activation of tyrosine kinase. Once the tyrosine kinase of IR is activated, it promotes
autophosphorylation of the β subunit, where phosphorylation of three tyrosine residues
(Tyr-1158, Tyr-1162, and Tyr-1163) is required for amplification of the kinase activity. Then
tyrosine kinase phosphorylates the insulin receptor substrate proteins (IRS 1 and 2) and
phosphotyrosine residues on IRS proteins become targets for the p85 regulatory subunit of
phosphatidylinositol 3-kinase (PI3-kinase).
The activated PI3-kinase generates higher levels of phosphotidylinositides, such as phospha‐
tidyl-inositol-3,4-bisphosphate (PIP2) and phosphatidyl-inositol-3,4,5-trisphosphate (PIP3),
which bind to the phosphoinositidedependent kinase-1 (PDK1). PDK1 can directly phosphor‐
ylate all protein kinase C (PKCs).
Downstream from PI3-kinase, activation of Akt (protein kinase B) produces its effects,
including those on gene transcription as well as glucose uptake through the translocation of
facilitative glucose transporter 4 (GLUT4) to the cell membrane.
Each step in this signaling cascade is a potential target for EDCs. EDCs interact and impair the
cellular insulin effect acting at different levels: on IRS, PI3-kinase, Akt, PDK or PKC or through
associated mechanisms. Some examples are included in figure 1.
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Figure 1. A schematic illustration of EDCs interference on insulin signaling pathways. Arrows represent an activation
process; X represent an inhibition process
For example, TCDD, arsenic or PCB alter IRS activity (especially IRS-1 phosphorylation)
through different mechanisms: TCDD increasing MAPK (mitogen-activated protein kinase)
activity and JNK (c-Jun N-terminal kinase) activity [83], arsenic decreasing p70-S6-kinase
activity [84] and PCBs increasing CaMK2 and MAPK 1 and 2 activity [80].
Other EDCs act on insulin-stimulated Akt phosphorylation. Akt phosphorylation is attenuated
by PCB-77 [65] or BPA [55]. Arsenic (III) exposure was also associated with suppression of AkT
phosphorylation and glucose uptake in 3T3-L1 adipocytes, causing an insulin resistant
phenotype [85,86].
BPA acts not only on Akt phosphorylation, but also stimulates tyrosine phosphorylation via
PI3-kinase, the global effect being the impairment of IRS activity [87].
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Additional studies have demonstrated that TCDD [83], BPA [88] or DEHP [89] are modulating
the insulin signalling cascade by down-regulation of the insulin receptors or acting on plasma
membrane GLUT4 level and antagonizing insulin action [90].
Also, cadmium induces impaired glucose tolerance by down-regulating GLUT4 expression in
adipocytes [91].
Inorganic arsenic (III) inhibits PDK-1 activity, thus suppressing PDK-1-catalyzed phosphory‐
lation of PKB/Akt and p-PKB/Akt–mediated translocation of GLUT4 transporters to the
plasma membrane [85,92].
5.4. Alteration of the intermediary metabolism
In addition to direct effects on the insulin signalling cascade, EDCs alter the intermediary
metabolism, mainly the gluconeogenesis. TCDD [63], or PCBs [93] have been shown to down-
regulate the expression of phosphoenolpyruvate carboxykinase (PEPCK), reducing its activity
and inducing hypoglicemia. In the case of PCBs, the suppression of hepatic PEPCK expression
was proportional to activation of the AhR, suggesting a direct correlation between AhR
activation and perturbation of the intermediary metabolism.
Alternative mechanisms are implicated in the development of T2DM, such as inflammation
or oxidative stress. For example, PCB-77 has been shown to promote expression of IL-6 and
TNF-α, leading to impaired insulin signalling in endothelial cells [64]. In addition to its effects
on TNF-α and IL-6, PCB-77 also increases expression of MCP-1, adipocyte-secreted molecule
that contributes to global insulin sensitivity [66].
BPA augments secretion of IL-6 and TNF-α, but simultaneously inhibits the release of
adiponectin in human adipose tissue explants [94]. The suppression of adiponectin release
could promote insulin resistance and increase the risk of developing the metabolic syndrome.
The same outcome is expected based on elevated IL-6 levels.
We should highlight the strong correlation between increased TNFα production and insulin
resistance [95]. TNFα affects insulin resistance by downregulating the glucose transporter,
interfering with IR phosphorylation and signaling, and by inhibiting transcription factors that
affect insulin sensitivity.
Some EDCs are acting on other nuclear receptors involved in fat metabolism and regulation
of glucose uptake, like PPARs (peroxisome proliferator-activated receptors), especially on
PPARγ which are involved in the regulation of adipocyte differentiation, production of
adipokines or insulin responsiveness [96]. By antagonizing PPARγ, EDCs significantly inhibit
the release of adiponectin that has insulin-sensitizing effects, as it enhances inhibition of
hepatic glucose output as well as glucose uptake and utilization in fat and muscle tissues. So,
adiponectin levels are correlated with insulin sensitivity, therefore supressing its biological
effects affects glucose homeostasis.
For example, BPA at 0.1 and 1 nM doses is a potent antagonist of PPARγ, which suppresses
adiponectin release in human adipose tissue explants [97]. In the same time, BPA influences
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adiponectin level via another mechanism that implies binding to protein disulfide isomerase
(PDI), a critical player in the retention of adiponectin in cells [98]
Interestingly, in vitro it was observed that ERβ can act as a negative regulator of PPARγ,
decreasing ligand-induced PPARγ and PPARγ induced adipogenesis [99], therefore it is
obvious that PPARγ function is affected by EDCs directly interacting with the receptor, but
also by EDCs that modulate ERβ activity. Also, TCDD inhibits adipogenesis through a
suppression of PPARγ [100].
Other EDCs such as phthalates (DEHP) act as potent agonists of PPARα or PPARγ. In rodent
models, PPARα appears to mediate high-dose DEHP-induced body weight loss [101], but these
effects can not be extrapolated to humans, taking into account that the levels required to
activate human PPARα are almost three times higher than the concentrations required to
activate mouse PPARα, and the maximum-fold induction is less for human PPARα than for
mouse PPARα [102].
In conclusion, the investigation of insulin signaling pathways may explain how EDCs
modulate insulin action, especially in the case of exposure to singular compound; however, in
the context of accidental or occupational exposures, humans are exposed to mixtures of
compounds and this complicates understanding the global biological effects. For example, if
different compounds are acting through the same pathway, but at different points, co-exposure
is likely to have additive or synergistic effects that promote the development of insulin
resistance and T2DM. Moreover, points of pathway convergence (e.g., IRS) might be the perfect
target of drug intervention to treat environmentally-mediated diabetes.
6. Evidence of T2DM in animal models after EDC exposure
There are enough published data in animal models that investigated the correlation between
EDCs exposure and T2DM. This correlation between exposure in the animal models and
alterations in glucose homeostasis, including hyperglycemia and glucose intolerance is crucial,
taking into account that epidemiological studies fail to establish a causality.
A number of examples are given below.
Repeated low dose of TCDD (500 ng/kg bw), administered orally, reduced glucokinase gene
expression, predicting a rise in blood glucose levels on C57BL/6 mice [103], while in diabetic
rats, a higher dose of 12.8 μg/kg bw TCDD had significantly reduced serum glucose levels by
day 8 of treatment [51]. Moreover, a single but high dose of TCDD (116 μg/kg bw i.p.) impaired
insulin-stimulated glucose uptake in C57BL/6 and DBA/2J mice [52].
Administration of 75 μg/kg bw DEHP for 14 days reduced insulin levels and raised serum
glucose levels in exposed female Wistar Kyoto rats [104]. Almost similar results were obtained
on male rats treated for a longer period (21 days) with diet supplemented with 2% (w/w) of
DEHP [105].
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Male mice treated orally with 0.5-50 μg/kg bw TBT for 45 days demonstrated hepatic steatosis,
hyperinsulinemia, hyperleptinemia and a reduction in hepatic adiponectin levels, in a dose-
dependent fashion, confirming PPARγ stimulation observed in vitro [106].
Similar results were obtained in adult Sprague-Dawley rats exposed for 28 days to crude
salmon oil containing POPs [107]. The animals developed insulin resistance syndrome,
abdominal obesity and hepatosteatosis, the contribution of POPs to insulin resistance being
confirmed also by the same authors in cultured adipocytes. These findings are important since
POPs are accumulating in the lipid fraction of fish, and fish consumption represents the main
source of POP exposure to humans.
Also coplanar PCBs (e.g. PCB-77 and PCB-126), at dosage of 50 mg/kg orally, impaired glucose
homeostasis in lean C57BL/6 mice and mitigate beneficial effects of weight loss on glucose
homeostasis in obese mice [66], while inorganic arsenic (III) administered in the drinking water
for 20 weeks, at doses of 25 or 50 ppm As/kg bw/day, impaired glucose tolerance in C57BL/6
mice in a dose-dependent manner [108].
In the animal studies mentioned before, not just blood glucose levels were investigated, but
other markers of insulin regulation, such as HOMA-IR, pancreatic production of NO, SOD and
CAT activity, in order to reflect the magnitude of the global disturbance. While most studies
have demonstrated perturbations in insulin action, some of them have shown improved
glucose tolerance or even hypoglycaemia. Acute exposure of adult male mice to high dosage
of BPA (100 μg/kg bw/day) produced a rapid hyperinsulinemia based on significant increase
in β-cell insulin content, as a direct result of BPA estrogenic properties [109], while sustained
exposure to lower dosage (10 μg /kg bw/day) impaired glucose tolerance and reduced the
hypoglycaemic effect of insulin, through a compensatory peripheral insulin resistance [54].
These results are easily correlated with non-monotonic dose response curve exhibited in
vitro by BPA.
Taking into account that EDCs alter glucose homeostasis and endocrine pancreatic function
not just in adult animals but also during pregnancy or in offspring, these effects were also
investigated in pregnant animals. For example, prenatal exposure to high dosage of diisobutyl
phthalate (600 mg/kg bw/day) from gestation Day 7 to Day 21 reduced plasma leptin and
insulin levels in male and female offspring, complementary to sexual distrurbance [110].
Maternal glucose intolerance was observed in pregnant mice exposed to inorganic arsenic (V)
at dosage of 9.6 mg/kg bw, this explaining the neural tube defects induced by arsenate [111].
In conclusion, all these examples regarding in vivo effects in animal models are highly
suggestive, taking into account that the experimental exposure is very close or even similar
with environmental human exposure. However, data on co-exposure are lacking, therefore
new studies should focus on this issue, in order to reveal possible additive, synergistic or
antagonistic effects exhibited by the mixtures.
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7. Epidemiological data linking EDCs exposure to T2DM
There is growing concern in the scientific community that EDCs may be contributing to the
high incidence of diabetes, particularly in young people.
Epidemiological studies (as occupational or population-based studies) but also disasters tried
to link, at least partially, the environmental exposure to EDCs with the development of T2DM.
We collected and compiled from a comprehensive scientific literature the most relevant
epidemiological studies concerning the T2DM and exposure to EDCs like TCDD, arsenic,
phthalates or BPA.
Disasters such as Seveso accident or exposure of military personnel during the Vietnam War
and follow-up studies have suggested a link between TCDD exposure and a higher incidence
of diabetes [112, 113, 114]. Other cross-sectional studies [115, 116] did not revealed such
correlation, while longitudinal studies that have been conducted are inconsistent [117].
Some poisoning cases reported during late 1970s have involved contaminated rice oil with
PCBs. PCB exposure was associated with an increased prevalence of diabetes in women [118].
Other prospective studies on PCB153 showed a positive association with T2DM, but taking
into account the variation across studies, it did not allow a metaanalysis. For example, five
studies used different diagnostic strategies and several approaches to address serum lipid
levels [119]. In addition, the age varied between cohorts from 18 to 30 years [119] to 70 years
[120] while gender was also inconsistent, exclusively female in one study [121], exclusively
male in another [119] and mixed in the remaining studies [120; 122, 123]. The temporal and
geographic variation among the studies induced significant differences in the exposure
assessment especially on duration of exposures or on the composition of the mixtures.
However, other variables must be considered in the interpretation of PCBs studies, such as the
use of PCB153 as a surrogate for total PCBs or the lack of data regarding kinetics of different
PCBs (especially on accumulation) that influence their current serum levels.
A closer evaluation of the cohorts described before revealed the non-monotonic exposure-
response relationships exhibited by PCBs: the risk of diabetes was significantly increased with
small increases within the lower ranges of PCBs concentrations, but only slightly increased
with significant increases in concentrations of PCBs. This non-monotonic relationship exhib‐
ited by PCBs in cohorts was also observed in brominated flame retardants studies, like those
conducted on PBDE-153 [124], but not in BPA cohorts, where BPA urinary levels were
associated with diabetes incidence in a dose-dependent manner [125].
Evaluation of studies conducted on EDCs (PCBs or TCDD) reveal that many of them focused
specific populations (e.g. occupational studies or exposure through industrial accidents or
disasters), so they might not reflect the actual risk of the general population. However, recent
investigations were done on representative sampling of the US population, using data from
the National Health and Nutrition Examination Survey (NHANES). For example, Lee et al.
[126] reported strong and highly significant associations, among participants in the NAHNES
study, between serum concentrations of POPs and the HOMA-IR insulin resistance values,
after correction for age, sex, BMI, and waist circumference.
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Study design Diagnosis Findings(95% CI)
As in drinking
water (µg/L) Exposure Ref.
Low-to-moderate exposures (< 150 µg/L drinking water)
Cross-sectional
[male
225 nonsmokers 209
smokers]
Self-report
Increased urinary
As in nonsmoking
diabetics
n.r.
Nonsmokers: 5.59 (diabetics)
vs. 4.7 (nondiabetics) μg As/L
Smokers: 7.27 (diabetics) vs.
5.41 (nondiabetics) μg As/L
(urine)
127
Cross-sectional
[n=11,319]
Self-report prior to
baseline
adjOR=1.24
(0.82- 1.87) 0.1–864
41–92 (Q3) vs. 0.1–8 (Q1) μg
As/L drinking water, CEI 128
Case–control
[n=144 female]
Fasting blood
glucose, OGTT
Increased As in
urine from
diabetics
n.r.
4.13 (diabetics) vs. 1.48
(nondiabetics) μg As/L in
urine
129
Retrospective
[41,282male
38,722 female]
Death certificate
Male SMR =1.28
(1.18-1.37)
Female SMR =1.27
(1.19- 1.35)
1.27–11.98 6 counties vs. state μg As/L(drinking water) 130
Case–control
[n=87] Not reported
RR=0.87
(0.5- 1.53) n.r.
75th vs. 25th percentile μg
As/L (urine) 131
Retrospective
[n=1,074 deaths] Death certificate
RR=1.6
(0.36- 7.16) n.r.
Residence time within 1.6 km
(1 mi): ≥ 10 years vs. < 1 year 132
Cross-sectional
[n=235] Hospital records
RR=1.098
(0.98- 1.231) 16–272
21–272 (range) vs. 16–38
(range) μg As/L (drinking
water)
133
Case–control
[n=117] Not reported
RR=1.09
(0.79- 1.49) n.r.
75th vs. 25th percentile μg
As/mL (plasma) 134
Cross-sectional
[n=1,185] Self-report
adjOR=1.02
(0.49 - 2.15) 0–2,389
> 10 vs. < 2 μg As/L (well-
water) 135
Cross-sectional
[n=788]
Fasting blood
glucose, self-report,
medication
adjOR=3.58
(1.18- 10.83) -
18 (≥ 80th) vs. 3.5 (≤ 20th
percentile) μg As/L (urine) 136
Cross-sectional
[n=1,279]
Fasting blood
glucose, self-report,
medication
adjOR=2.60
(1.12 - 6.03) -
7.4 (80th) vs. 1.6 (20th
percentile) μg As/L (urine) 137
Cross-sectional
[n=795]
Fasting blood
glucose, self-report,
medication
adjOR=1.15
(0.53 - 2.50) -
12 (≥ 80th) vs. 2.7 ( ≤ 20th
percentile) μg As/L (urine,
not adjusted for creatinine)
138
Study design Diagnosis Findings(95% CI)
As in drinking
water (µg/L) Exposure Ref.
High exposure (≥ 150 µg/L drinking water)
Cross-sectional
[n=11,319]
Self-report prior to
baseline
adjOR=1.11
(0.73- 1.69) 0.1–864
176.2–864 (Q5) vs. 0.1–8 (Q1)
μg As/L drinking water, CEI 134
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Study design Diagnosis Findings(95% CI)
As in drinking
water (µg/L) Exposure Ref.
Cross-sectional
[n=891]
Self-report, OGTT,
treatment history
adjOR=10.05
(1.3-77.9) 700–930
≥ 15 vs. 0 ppm-year drinking
water, CEI 141
Case–control
[n=235] Glucose, blood
OR=2.95
(0.954, - 9.279) 3–875
218.1 μg As/L vs. 11.3 μg As/
L(mean) 140
Cross-sectional
[n=1,107]
Self-report, OGTT,
glucosuria
adjPR=5.2
(2.5- 10.5) 10–2,100 Keratosis vs. non-keratosis 141
Retrospective
[n=19,536] Death certificate
SMR=1.46
(1.28- 1.67) 250–1,140
Blackfoot endemic region vs.
national reference 142
Prospective
[n=446]
Fasting blood
glucose, OGTT
RR=2.1
(1.1- 4.2) 700–930
≥ 17 vs. < 17 mg/L-year As
(drinking water, CEI) 143
Cross-sectional
[n=706,314] Insurance claims
adjOR=2.69
(2.65- 2.73) 350–1,140
Endemic vs. non-endemic
region 144
Abbreviations: 95% CI – confidence interval 95%; adjOR-adjusted odds ratio; adjPR-adjusted prevalence ratio; As-ar‐
senic; CEI, cumulative exposure index; OGTT-oral glucose tolerance test; Q-quintile; RR-relative risk; SMR-standar‐
dized mortality ratios; n.r. – not reported
Table 3. Association between arsenic and diabetes
The correlation between the level of arsenic in drinking water and the incidence of T2DM
was extensively investigated. The published cohorts were categorized based on the level of
exposure  (table  3)  in  order  to  identify  the  correlation  between  exposure  and  critical
endpoints.  In  addition  to  diabetes,  epidemiological  studies  have  associated  exposure  to
arsenic with other measures of disturbed glucose homeostasis, such as glucose tolerance or
metabolic syndrome.
Preliminary analysis on the existing human data provide limited support for an association
between arsenic and diabetes in populations exposed to relatively high levels (≥ 150 μg As/L
in drinking water), but the evidence is insufficient to conclude that exposure to low to moderate
level is associated with diabetes. However, a major gap is obvious. The measurement of arsenic
in drinking water supplies, which was often used to assess arsenic exposure, is not appropriate
to calculate the internal dose, taking into account individual variation in arsenic uptake and
metabolism. Also, individual information on the duration and timing of exposure, which is
critical, especially for estimating cumulative exposure, are missing.
Regarding phthalates, cohort studies were mainly focused on correlation between exposure
and obesity and less on T2DM. However, those found were done on representative sampling
of the US population, using data from NHANES. For example, Stahlhut et al. [145] investigated
1,292 adult US male participants in the NHANES 1999–2002 and revealed that urinary
concentrations of three phthalate metabolites (mono-n-butyl phthalate, monobenzyl phthalate
and monoethylphthalate) were associated with increased insulin resistance, assessed by
HOMA-IR. In addition, phthalates levels were associated with increased waist circumference.
A similar association between urinary phthalate metabolite concentrations, body mass index
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and waist circumference was found in another cross-sectional study of NHANES data [146].
However, considering the methodological limitations of the existing data, there is no sufficient
evidence to conclude there is a correlation between phthalates and diabetes or obesity.
The epidemiological data on BPA and T2DM is less consistent compared with POPs, but is
growing. There are two cross-sectional analyses of NHANES data 2003-2008 that reported a
positive associations of BPA exposure (median 2.5 and 1.8 μg/l) with self-reported diagnosis of
diabetes [125, 147]. However, these analyses have an important weakness that limits their value:
the use of a single spot urine sample collected concurrent with the information on diagnosis of
diabetes. The single spot sample reflects only recent BPA exposure, so cannot be extrapolated
to longer period (like years or decades) which is relevant for the development of diabetes. Other
large cross-sectional studies on BPA in China provide conflicting data [148,149].
A closer evaluation of all epidemiological studies on EDCs reveals some weaknesses, such as
the assessment of one compound as a surrogate for total mixture (in case of PCBs), the lack of
data regarding kinetics, especially on accumulation in lipid-rich tissues (in case of POPs),
limited type of biological material used for direct measurement EDCs (serum or urine) or
environmental measurement which is not appropriate to calculate the internal dose (in case of
As). Other caveats must be considered in the interpretation of studies, such as heterogeneity
in the definition of diabetes or insulin resistance.
8. Challenges in EDCs research
There are a number of challenges limiting our understanding of the impact of EDCs on T2DM
related to the physical properties of EDCs: the selection of experimental models to assess effects
on glucose homeostasis or coexisting risk factors on the exposed individuals included in the
epidemiological studies.
The thousands of chemicals released into the environment create the real scenario of human
co-exposure and an enormous analytical challenge in the assessment. Sometimes the physical
properties of EDCs such as lipophilicity contribute to their accumulation and persistence in
human tissues, even after the exposure has terminated. In this case biomonitoring is the key
for the assessment of EDCs. Regarding the types of sample used in analysis, these must be
expanded beyond urine and serum to lipid-rich organs (e.g., POPs are accumulated in brain
and adipose tissue) as well as tissues relevant to in utero and early postnatal stages of exposure
(e.g., human breast milk). Also the development of clinical biomarkers it will be useful to
identify chemically exposed population.
Although environmental and tissue levels of certain EDCs (e.g., PCBs) have declined in some
countries in response to EU regulations, they remain of concern in other countries, and
uncertainty still exists regarding future trends.
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Another important challenge is related with the lack of clear structure-function relationships
that excludes a possible in silico prediction of endocrine disrupting effects and demands the
use of bioassays to characterize the physiological effects of the exposure.
The experimental design is further complicated by non-monotonic dose response correlation,
multiple mechanisms of action for a single compound, potential additive, synergistic or
antagonistic effects observed during co-exposure or the lack of adversity for some endpoints
defined in OECD guideline (e.g. uterotrophic assay).
The main gaps of epidemiological studies were already addressed. Still other factors like
geographic and temporal variation among the studies can induce differences in the exposure
assessment, especially on the composition of chemical mixtures (especially for POPs) and
duration of exposure.
Also inter-individual variation, transgenerational effects or predisposing factors (such as
obesity or a family history of diabetes) may influence the metabolic effects observed in the
epidemiological studies.
9. Conclusion
More studies are necessary to establish the exact mechanisms through which EDCs determine
impairments of glucose homeostasis; these studies are imperatively important in order to
impose international guidelines that will lead to a reduction of the incidence of T2DM cases
induced by chemical exposure.
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